https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html

I've been digging through every piece of legislation I can find. This one is different. The SAFE Drug Act was introduced November 19th and it's clearly written to kill compounded GLP-1s: → 20 compounded prescriptions per month. That's it. Total. → New definition of "essentially a copy" that captures almost every semaglutide and tirzepatide script → Mandatory FDA reporting for out-of-state compounding (aka the entire telehealth model) → 503B outsourcing facilities get hit with pharma-level oversight → Uncapped FDA fees This is different from Import Alert 66-80. That one creates supply friction. This one makes the business model illegal. BUT—and this is important—this still doesn't explain what's happening in the research space. This bill targets compounding pharmacies, not research companies. So why are vendors liquidating and pointing to 12/31? There's something else out there I haven't found yet. Full breakdown of every section of the bill 👇 https://open.substack.com/pub/derekpruski/p/the-safe-drug-act-the-compounding?r=4jq1x8&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

Do your research subjects experience a crash around day 6 or 7? It's a common pattern researchers observe... Days 1-4: Strong response. Minimal appetite signaling. Low food-seeking behavior. Days 5-6: Effects softening. Appetite signals returning. Day 7: Significant hunger response. Waiting on next administration. This isn't a flaw in the research protocol. It's basic pharmacokinetics. Here's what the data shows: Even with tirzepatide's ~5-day half-life, by day 7, circulating levels drop to roughly 60-65% of peak concentration. Receptor occupancy decreases proportionally. But what if you could maintain more stable levels throughout the research period? Same total weekly dose. Same mg. Just redistributed. → Reduced peak-related side effects → No end-of-week trough effects → More consistent receptor activation → Flatter concentration curve I wrote a deep dive breaking down: ✓ Why these compounds accumulate and why dose increases before week 4 skew results ✓ The math behind steady state ✓ Why clinical trials use once-weekly protocols (hint: it's about adherence, not optimization) ✓ Which research scenarios benefit from split dosing ✓ Practical protocols and considerations Full article with all the mechanisms 👇 https://open.substack.com/pub/derekpruski/p/split-dosing-glp-1s-why-smaller-more?utm_campaign=post-expanded-share&utm_medium=web Drop a comment if you've experimented with split dosing in your research—curious what others have observed.

Everyone's losing their minds over Eli Lilly doomsday scenarios - generic tirz flooding the market, potential crackdowns, the research peptide space collapsing, etc. Here's something interesting: Eli Lilly doesn't own survodutide. Boehringer Ingelheim does. So even if every single worst-case scenario about sema, tirz, and reta comes true... survodutide operates in a completely different corporate universe with different timelines, different patents, different legal strategies. Different company = different dynamics = different risks. Just something to keep in mind when everyone's panicking about one pharmaceutical giant. The peptide space isn't a monolith, and not every compound is tied to the same corporate fate. This isn't investment or medical advice - just pointing out that the industry has more moving pieces than people realize. What are your thoughts? Are people too focused on Eli Lilly and missing the bigger picture?

Quick reminder about all this fear mongering is going on with the GLP ones. Established the healthy lifestyle habits, and it’ll make your journey a lot easier. Whether it’s going on a walk with your family hitting the gym or playing a sport get out there and get active.